MAR

• Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board

  23 September 2025

• Kancera initiates process to seek stakeholders for a reverse take over

  18 September 2025

• Kancera terminates letter of intent with Recardio

  12 August 2025

• Kancera reports positive top-line results from the KANDOVA study

  13 June 2025

• Kancera reports positive outcome of pre-IND meeting with FDA

  5 June 2025

• Kancera signs letter of intent agreement with Recardio for licensing of KAND567 and KAND145

  7 March 2025

• Kancera resolves on a rights issue of approximately SEK 121.9 million

  23 February 2024

• Kancera reports positive top line results from the FRACTAL study

  20 December 2023

• Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023

  13 October 2023

• Kancera provides operational update in connection with release of financial interim report for second quarter

  18 August 2023